EVALUATION OF CGM USE FEATURES IN ADOLESCENTS WITH TYPE 1 DIABETES (T1D): A REPORT FROM THE CGM INTERVENTION IN TEENS AND YOUNG ADULTS (CITY) STUDY
- Laurel H. Messer, United States of America
- Laurel H. Messer, United States of America
- Lauren G. Kanapka, United States of America
- Mark A. Clements, United States of America
- Daniel Desalvo, United States of America
- Kellee Miller, United States of America
- Jennifer Sherr, United States of America
- Ruth S. Weinstock, United States of America
- Lori Laffel, United States of America
Abstract
Background and Aims
To describe use of continuous glucose monitoring (CGM) by adolescents and young adults with T1D enrolled in the CITY trial.
Methods
Participants (N=153) were randomized to CGM (Dexcom G5) or blood glucose (BG) monitoring for 26 weeks, with CGM users receiving educational support. Data on use of CGM are reported for the CGM group (n=74, mean age 18 ± 3 years, 45% female).
Results
At 26-weeks, 86% of participants were using CGM with average use 6.4 (3.5, 7.0) days/week (median, Q1, Q3). Median daily blood glucose (BG) checks in this group was 2.0 (1.8, 3.0) with 98% regularly using CGM readings without a confirmatory BG for insulin dosing (table). Most participants utilized low and high alerts (91% and 84%, respectively), with median low alert setting at 70 mg/dl (70, 80) and median high alert setting at 270 mg/dl (240, 300). The mobile app was used to view CGM data by 81% of participants and 62% of these users shared CGM data via remote monitoring. Most were sharing with one (59%) or two (28%) people: parents/guardians (91%), siblings (13%) and significant others (9%).
Conclusions
In the CITY trial, the majority of adolescents/young adults were using CGM regularly after 6-months, in contrast to previous descriptions of CGM use in this age group. Participants maintained high use of the mobile app, alerts and share features, possibly related to close follow up and education after CGM initiation. Future analyses should assess use of which features predict glycemic improvements.